Clinical Trial: Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232641) titled 'Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic' on Nov. 14.

Brief Summary: "Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulations than medications for other substance use disorders, including medication for alcohol use disorder (MAUD), which created barriers to MOUD initiation and retention. These barriers were exacerbated by physic...